News

08 Nov 2017

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

Press release: REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
Read More >>

08 Nov 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017
Read More >>

07 Nov 2017

Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference

REPROCELL Europe Ltd's CSO Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference
Read More >>

27 Sep 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017. The article is in the EPR’s section, Applied Research, Development and Production. It is co-authored by David Bunton at REPROCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia.
Read More >>

1 2 3 4 >>

Biopta is attending the Safety Pharmacology Society conference in Prague

23/09/2015

Biopta are attending the Safety Pharmacology Society conference in Prague, Monday 28th Sep - Thursday 1st October.

Come and meet Biopta at booth 3 to find out how predictive tests in fresh human tissues can add significant value to your compounds.

Dr Keith Bowers will be delivering a presentation titled 'The Relevance of Functional Studies with Fresh Human Isolated Tissues for the Assessment of Safety and Efficacy' on Wednesday 30th September Meeting Hall V at 17:15. An overview of the presentation is provided below.

Human functional tissues are increasingly being used to assess the safety of preclinical drug candidates. Human fresh tissues have long been considered the closest possible model of human pharmacology because they closely retain the tissue phenotype and can be used to measure a wide range of pharmacological responses. Despite this, relatively little drug development is conducted using fresh human tissue because of the perceived logistical and ethical difficulties surrounding the availability of tissue and practicalities of experimental work.

Overcoming the barriers to uptake of human tissue research remains a challenge and will be supported by clear evidence of the benefits of such an approach. It is also important to point out that such assays do not by themselves completely replace existing safety tests but contribute to a platform of evidence that increases the probability of clinical success and reduces the risk that species differences will go undetected.

Live chat by BoldChat